IP Verse

Pharmaceutical Preparation Containing Oxycodone And Naloxone - EP2425824

The patent EP2425824 was granted to Euro Celtique on May 10, 2017. The application was originally filed on Apr 4, 2003 under application number EP11177516A. The patent is currently recorded with a legal status of "Revoked".

EP2425824

EURO CELTIQUE
Application Number
EP11177516A
Filing Date
Apr 4, 2003
Status
Revoked
Feb 7, 2020
Grant Date
May 10, 2017
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (11)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

ZENTIVAFeb 9, 2018HARTVICHOVAADMISSIBLE
TEVA PHARMACEUTICALSFeb 8, 2018D YOUNGADMISSIBLE
INTAS PHARMACEUTICALSFeb 5, 2018ACCORD HEALTHCAREADMISSIBLE
STADA ARZNEIMITTELJan 17, 2018KERNEBECKADMISSIBLE
G L PHARMANov 9, 2017KESCHMANNADMISSIBLE
ETHYPHARMNov 7, 2017REGIMBEAUADMISSIBLE
ACINO PHARMAJul 3, 2017BREUERADMISSIBLE
KRKAJun 9, 2017HOFFMANN EITLEADMISSIBLE
GLENMARK PHARMACEUTICALS EUROPEMay 29, 2017SCHLICHADMISSIBLE
DEVELCO PHARMA SCHWEIZMay 11, 2017TER MEER STEINMEISTER & PARTNERADMISSIBLE
HEXAL SANDOZMay 11, 2017TER MEER STEINMEISTER & PARTNERADMISSIBLE

Patent Citations (35) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONDE4325465
DESCRIPTIONEP0352361
DESCRIPTIONUS3773955
DESCRIPTIONUS3966940
DESCRIPTIONUS4457933
DESCRIPTIONUS4582835
OPPOSITIONCA2273353
OPPOSITIONDE10215067
OPPOSITIONDE10215131
OPPOSITIONDE4325465
OPPOSITIONEP0352361
OPPOSITIONEP0960619
OPPOSITIONEP1492505
OPPOSITIONEP2425824
OPPOSITIONUS3773955
OPPOSITIONUS3966940
OPPOSITIONUS4457933
OPPOSITIONUS4769372
OPPOSITIONUS4987136
OPPOSITIONUS5549912
OPPOSITIONUS6419959
OPPOSITIONWO0132180
OPPOSITIONWO0158447
OPPOSITIONWO0158451
OPPOSITIONWO02092060
OPPOSITIONWO03007802
OPPOSITIONWO03084520
OPPOSITIONWO9825613
OPPOSITIONWO9932119
OPPOSITIONWO9932120
SEARCHDE4325465
SEARCHUS4457933
SEARCHWO0158447
SEARCHWO9932119
SEARCHWO9932120

Non-Patent Literature (NPL) Citations (47) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- Die Schmerzbehandlung von Turnorpatienten, THIEME, (1994), vol. 3-
DESCRIPTION- NOLTE, T, STK-ZEITSCHRIFT FüR ANGEWANDTE SCHMERZTHERAPIE, (2001), vol. 2-
DESCRIPTION- ZECH, D., GROND, S., LYNCH, J., HERTEL, D., LEHMANN, K., "Validation of World Health Organisation Guidelines for Cancer Pain Relief: a 10-year prospective study", PAIN, (1995), vol. 63, pages 65 - 76-
OPPOSITION- A.T. SKARIN et al., "Cancer Pain Management : II", Hospital Physician Board Review Manual: Oncology, (20000000), vol. 5, pages 1 - 12, XP055298164-
OPPOSITION- A.T. SKARIN et al., "Cancer Pain Management: II", Hospital Physician Board Review Manual: Oncology, (20000000), vol. 5, pages 1 - 12, XP055298164-
OPPOSITION- "Chapter 2 and part 11", ZENZ et al., Lehrbuch der Schmerztherapie, Stuttgart, Wissenschaftliche Verlagsgesellschaft mbH, (20010000), pages 255 - 280 , 462-463, XP055464217-
OPPOSITION- CULPEPPER-MORGAN J et al., "Oral naloxone treatment of narcotic induced constipation: dose response", Nida Research Monograph, (19890000), vol. 95, pages 399 - 400, XP055298251-
OPPOSITION- CULPEPPER-MORGAN J et al., "TREATMENT OF OPIOID-INDUCED CONSTIPATION WITH ORAL NALOXONE: A PILOT STUDY", Clin Pharm Ther, (19920000), vol. 52, pages 90 - 95, XP009062715-
OPPOSITION- "Eudragit product information", Evonik Nutrition & Care GmbH, pages 1 - 15-
OPPOSITION- "Ficha Tecnica l'OxyContin® 5mg, 10mg, 20mg, 40mg, 80mg", Ministro de sanidad Politica Social E Igualdad, (19980000), XP055436947-
OPPOSITION- "Kapitel 9", Schwabe U. et Al, Arzneiverordnungsreport, Springer, (20170000), pages 242 - 243, XP055464222-
OPPOSITION- "l'Oxygesic®", Rote Liste, (20010000), XP055436917-
OPPOSITION- Merck Index. 12th ed., (19960000), pages 1092 - 1093, 1194, XP055464231-
OPPOSITION- Mundipharma, "Targin", Fachinformation-
OPPOSITION- M. ZENZ et al., Lehrbuch der Schmerztherapie, (20010000), pages 463 - 464, XP055391902-
OPPOSITION- M. ZENZ et al., Lehrbuch der Schmerztherapie, Grundlagen, Theorie und Praxis für Aus-und Weiterbildung, (20010000), pages 463 - 464, XP055298154-
OPPOSITION- M. ZENZ et al., Lehrbuch der Schmerztherapie: Grundlagen, Theorie und Praxis für Aus- und Weiterbildung, Stuttgart, page 462, 463, 467 and 881, ISBN 3804718051, XP055298289-
OPPOSITION- "Naloxon", Europäisches Arzneibuch. 4. Auflage (Ph.Eur. 4), (20020000), pages 2442 - 2443, XP055464234-
OPPOSITION- "Neue Therapieperspektiven mit retardiertem Tilidin/Naloxon", Der Anaesthesist, (19980000), vol. 47, no. 5, pages 1 - 4, XP055383052-
OPPOSITION- "Neue Therapieperspektiven mit retardiertem Tilidin/Naloxon", Der Anaesthesist, (19980500), vol. 47, no. 5, pages 1 - 4, XP055383052-
OPPOSITION- "Optimization of Naloxone - Oxycodone ratio in pain patients", Study Protocol OXN 2401, (20011207), XP055298247-
OPPOSITION- "Oxigesic 5mg, 10mg, 20mg, 40mg, 80mg Reatardtabletten Product Information", MundiPharma, (20160700), pages 1 - 5, XP055399053-
OPPOSITION- "Oxycontin@", Vidal 2002, (20030000), pages 155 - 156, XP055436949-
OPPOSITION- "Oxygesic®", Rote Liste, (20010000), page 05025, XP055464219-
OPPOSITION- "Oxygesic®", Rote Liste, (20010000), pages 05023 - 05030, ISBN 3871932450, XP055385730-
OPPOSITION- Prof. Michael Zenz et al, Lehrbuch der Schmerztherapie, (20010000), page 462-463, 467, 881, ISBN 3804718051, XP055298289-
OPPOSITION- "Section III - Drugs Acting on the Central Nervous System", L. GOODMAN et al., Goodman & Gilman's The Pharmacological Basis of Therapeutics, (19960000), pages 550 - 551, ISBN 0071133488, XP055436950-
OPPOSITION- SKARIN et al., "Cancer Pain Management II", Oncology, (20000000), vol. 5, pages 1 - 12, XP055298164-
OPPOSITION- TH. FLÖTER et al., "Tilidin/Naloxon retard zur Langzeitanwendung bei chronischen Schmerzen und Multimorbidität", Fortschritte der Medizin, (20020000), vol. 120, no. 1, pages 29 - 35, XP055264063-
OPPOSITION- "Valoron® N retard", Rote Liste, (20161100), pages 1 - 5, XP055399182-
OPPOSITION- "Valoron®", Rote Liste, (20010000), pages 05095 - 05104, XP055385737-
OPPOSITION- ZENZ et al., Lehrbuch der Schmerztherapie: Grundlagen, Theorie und Praxis für Aus- und Weiterbildung, Stuttgart, (20010000), pages 463 - 464, XP055298154-
OPPOSITION- I. JURNA et al., "Retardiert freigesetztes Naloxon oral: Aufhebung der Obstipation durch orales Morphin ohne Beseitigung der Analgesie", Der Schmerz, (19930000), vol. 7, pages 314 - 321, XP009176556
OPPOSITION- I. JURNA et al., "Retardiert freigesetztes Naloxon oral: Aufhebung der Obstipation durch orales Morphin ohne Beseitigung der Analgesie. [Oral administration of slow-release naloxone for prevention of constipation but not analgesia following oral morphine", Der Schmerz, (19930000), vol. 7, no. 4, pages 314 - 321, XP009176556
OPPOSITION- Jurna et al., "Retardiert freigesetztes Naloxon oral: Aufhebung der Obstipation durch orales Morphin ohne Beseitigung der Analgesie", Der Schmerz, (19930000), vol. 7, pages 314 - 321, XP009176556
OPPOSITION- LATASCH et al., "Aufhebung einer Morphin- induzierten Obstipation durch orales Naloxon", Anaesthesit, (19970000), vol. 46, pages 191 - 194, XP055104659
OPPOSITION- Mueller-Lissner, "Fixed combination of oxycodone with naloxone: a new way to prevent and treat opioid-induced constipation", ADVANCES IN THERAPY, (20100000), vol. 27, no. 9, pages 581 - 590, XP055462846
OPPOSITION- Jurna et al., "Oral naloxone reduces constipation but not antinociception from oral morphine in the rat", Neuroscience Letters, (19920000), vol. 142, pages 62 - 64, XP024349821
OPPOSITION- MEISSNER et al., "A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation", European Journal of Pain, (20090000), vol. 13, no. 1, pages 56 - 64, XP025865529
OPPOSITION- Meissner et al., "A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation", EUROPEAN JOURNAL OF PAIN, (20090000), vol. 13, pages 56 - 64, XP025865529
OPPOSITION- MEISSNER et al., "A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation", Europ. J. of Pain, (20080000), vol. 13, pages 56 - 64, XP025865529
OPPOSITION- W. MEISSNER et al., "A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation", Eur. J. Pain, (20090000), vol. 13, pages 56 - 64, XP025865529
OPPOSITION- MEISSNER W et al., "Oral naloxone reverses opioid-associated constipation", Pain, (20000000), vol. 84, pages 105 - 109, XP055252526
OPPOSITION- Liu et al., "Low-Dose Oral Naloxone Reverses Opioid-Induced Constipation and Analgesia", JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, (20020100), vol. 23, no. 1, pages 48 - 53, XP055252523
OPPOSITION- HAWKES ND et al., "Effect of an enteric-release formulation of naloxone on intestinal transit in volunteers taking codeine", Aliment Pharmacol Ther, (20010000), vol. 15, pages 625 - 630, XP055408359
OPPOSITION- N.D. HAWKES et al., "Effect of an enteric-release formulation of naloxone on intestinal transit in volunteers taking codeine", Aliment Pharmacol Ther, (20010500), vol. 15, no. 5, pages 625 - 630, XP055408359
OPPOSITION- Sykes NP, "An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer", Palliative Medicine, (19960000), vol. 10, pages 135 - 144, XP055298264

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents